Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.

@article{Bertelloni2008TreatmentOC,
  title={Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.},
  author={Silvano Bertelloni and Dick Mul},
  journal={Asian journal of andrology},
  year={2008},
  volume={10 4},
  pages={
          525-34
        }
}
In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the last years, relevant improvements in the treatment of CPP have been achieved. Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety. In the present paper, recent advances of CPP management with GnRH analogs in men… 

Tables from this paper

MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.
TLDR
GnRHa treatment appears to improve adult height in girls with CPP, especially if diagnosed before the age of 6, whereas a real benefit in terms of adult height is still controversial in patients with the onset of puberty between 6 and 8 years of age.
Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties
TLDR
This review updates GnRH analog treatment in CPP by a search of the literature published on the topic since 1980, and concludes that new very long-acting Gn RH analogs (quarterly or yearly formulations) may improve compliance with therapy, but longer follow-up studies are needed.
Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty
TLDR
GnRHa treatment significantly improved the growth potential and FAH in boys with CPP and was significantly correlated with the target height.
Midterm and Long-Term Impacts of GnRH Agonists Treatments
TLDR
GnRH analogs treatment is effective on final height, especially when treatment is started before the age of 6 years old, and does not seem to alter fertility of men and women treated during their infancy.
Precocious Puberty Therapeutic Management: GnRH Analogs Treatment
TLDR
GnRH analog therapy is an effective treatment for central precocious puberty and compromise of adult height, early menarche, and social and behavioral implications is often a concern for patients.
Central Precocious Puberty in Boys and Girls: Similarities and Differences
Central precocious puberty (CPP) is due to the premature activation of the hypothalamic–pituitary–gonadal axis, which is responsible for the appearance of secondary sexual characteristics. It occurs
The use of GnRH agonists in precocious puberty.
In this review several aspects of gonadotrophin releasing hormone agonists (GnRHa) treatment in central precocious puberty (CPP) are highlighted. These include issues of the definition of precocity,
Triptorelin depot for the treatment of children 2 years and older with central precocious puberty
TLDR
Triptorelin depot treatment of CPP should be restricted to tertiary pediatric endocrinology centers, considering that some uncertainties still exist and that rare but serious adverse events may occur.
Gonadotropin-Releasing Hormone Agonist Treatment in Sexual Precocity.
TLDR
Depot gonadotropin-releasing hormone (GnRH) analogs represent the first-line therapy in sexual precocity due to central precocious puberty and few studies have focused on the establishment of the 1st menstruation, 1st sexual intercourse, socioprofessional outcome and subsequent fertility.
...
...

References

SHOWING 1-10 OF 73 REFERENCES
Effect of Gonadotropin-Releasing Hormone Agonist Treatment in Boys with Central Precocious Puberty: Final Height Results
TLDR
GnRHa treatment in boys results in a FH close to target height, and regional differences in height gain were observed between the different countries, reflecting different local practices.
Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy.
TLDR
It was found that the patients' mean +/- SD peak GnRH-stimulated LH and FSH had returned to the normal range by 1 yr after stopping therapy, and whereas testosterone returned to normal levels by1 yr, the Patients' testis volume remained smaller than normal until 2 yr after therapy.
Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
TLDR
Results indicate that dLA (7.5 mg, im, every 4 weeks) does not produce complete desensitization in all children with CPP and suggest that overnight monitoring of LH release is more sensitive than GnRH stimulation testing for the assessment of dLA dose adequacy.
Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.
TLDR
Long acting GnRH therapy is effective in improving the auxological outcome of patients with central isosexual precocious puberty and maximum benefit is observed in girls with greater bone age advancement treated at a younger age and for a longer duration of treatment.
Final Height after Gonadotrophin Releasing Hormone Agonist Treatment for Central Precocious Puberty: The Dutch Experience
TLDR
In girls, GnR Ha treatment seems to restore FH into the target range, and a younger age and advanced bone age at start of treatment are associated with more height gain from GnRHa treatment.
Central precocious puberty : Short-term comparative data of treatment with monthly or long-acting three months depot triptorelin
TLDR
Triptorelin 11.25 mg/3 months is able to suppress the LH peak to prepubertal values in 100% of examined patients at 3 and 6 months of therapy, suggesting that the new formulation is as effective as the monthly formulation, and that it can be the initial treatment in girls with CPP.
Auxological outcome and time to menarche following long‐acting goserelin therapy in girls with central precocious or early puberty
TLDR
This study determined the auxological parameters and timing of menarche or re‐menarche in all girls with CEP/CPP who have completed a course of Zoladex LA treatment and the secondary aim was to assess auxological outcome in girls who have attained final height.
Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
TLDR
This study demonstrates that not all patients with apparent idiopathic precocious puberty require medical treatment, notably when there is no evidence of hypothalamo-pituitary ovarian activation or no significantly advanced BA to impair height potential.
Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
TLDR
Most girls with idiopathic CTPP treated by GnRH agonists may achieve an adult height within the population norm and/or their target range and the most favorable height prognosis with respect to TH is generally observed in the subjects with the tallest height at the end of treatment and the lowest BA2:CA2 ratio.
...
...